DXCM DexCom, Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: DXCM

Price (delayed)

$411.15

Market cap

$39.36B

P/E Ratio

184.37

Dividend/share

N/A

EPS

$2.23

Enterprise value

$40.58B

Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.dexcom.com
DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Highlights

The company's equity has surged by 97% YoY and by 45% QoQ
DXCM's gross profit is up by 43% year-on-year and by 8% since the previous quarter
The debt has soared by 61% YoY and by 50% from the previous quarter

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
95.74M
Market cap
$39.36B
Enterprise value
$40.58B
Valuations
Price to earnings (P/E)
184.37
Price to book (P/B)
28.04
Price to sales (P/S)
22.47
EV/EBIT
147.68
EV/EBITDA
122.86
EV/Sales
23.65
Earnings
Revenue
$1.72B
EBIT
$274.8M
EBITDA
$330.3M
Free cash flow
$209M
Per share
EPS
$2.23
Free cash flow per share
$2.23
Book value per share
$14.66
Revenue per share
$18.29
TBVPS
$37.35
Balance sheet
Total assets
$3.52B
Total liabilities
$2.17B
Debt
$1.75B
Equity
$1.35B
Working capital
$2.63B
Liquidity
Debt to equity
1.29
Current ratio
7.58
Quick ratio
7.01
Net debt/EBITDA
3.69
Margins
EBITDA margin
19.2%
Gross margin
63.9%
Net margin
11.9%
Operating margin
15.1%
Efficiency
Return on assets
7.8%
Return on equity
20.8%
Return on invested capital
9%
Return on capital employed
8.8%
Return on sales
16%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$1.72B
Gross profit
$1.1B
Operating income
$258.9M
Net income
$204.7M
Gross margin
63.9%
Net margin
11.9%
The net margin has soared by 185% YoY and by 29% from the previous quarter
DXCM's gross profit is up by 43% year-on-year and by 8% since the previous quarter
Dexcom's revenue has increased by 41% YoY and by 7% from the previous quarter
Dexcom's net income has increased by 38% from the previous quarter

Valuation

What is Dexcom stock price valuation
P/E
184.37
P/B
28.04
P/S
22.47
EV/EBIT
147.68
EV/EBITDA
122.86
EV/Sales
23.65
The EPS rose by 38% QoQ
The company's equity has surged by 97% YoY and by 45% QoQ
DXCM's P/B is 30% above its 5-year quarterly average of 21.5 and 19% above its last 4 quarters average of 23.6
The stock's price to sales (P/S) is 84% more than its 5-year quarterly average of 12.2 and 47% more than its last 4 quarters average of 15.3
Dexcom's revenue has increased by 41% YoY and by 7% from the previous quarter

Efficiency

How efficient is Dexcom business performance
Dexcom's ROA has soared by 181% YoY and by 20% from the previous quarter
The ROE has soared by 179% year-on-year and by 15% since the previous quarter
The ROS rose by 19% QoQ
DXCM's return on invested capital is up by 6% since the previous quarter

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 63% higher than its total liabilities
The company's total assets has surged by 71% YoY and by 44% QoQ
The total liabilities has surged by 57% year-on-year and by 43% since the previous quarter
The debt is 29% more than the equity
The company's equity has surged by 97% YoY and by 45% QoQ
The debt has soared by 61% YoY and by 50% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.